Norstella

What Norstella does

Norstella is a global life sciences intelligence company that sells AI-powered data, analytics, and consulting solutions to pharmaceutical, biotech, medtech, and clinical research organizations. The company was formed through the November 2022 merger of Norstella and Citeline, valued at approximately $5 billion, and now operates six market-leading brands — Citeline (clinical trial intelligence and pipeline data), Evaluate (market forecasting and commercial intelligence), MMIT (real-world data on drug coverage and patient access), Panalgo (healthcare data analytics), Skipta (HCP digital engagement across 50+ specialty communities), and The Dedham Group (market access consulting). Its central platform, NorstellaLinQ, is described as the biopharma industry's first fully integrated data asset, combining 74+ billion linked data points spanning open and closed claims, lab results, structured EMR, and proprietary forecasting, clinical, regulatory, payer, and commercial intelligence.

The company monetizes primarily through annual enterprise subscriptions sold via direct field sales to pharma and biotech clients across the drug development lifecycle. Norstella AI — trained on cleansed, tokenized proprietary data — powers brand-specific AI features including Evaluate Ask Ella (conversational RAG over commercial intelligence), Panalgo Ella AI (plain-language cohort building), MMIT Searchlight (AI policy summarization), Norstella Atlas (sourced deliverable generation), and Citeline Protocol Smart Design (auto-generation of trial endpoints and inclusion/exclusion criteria). The company reports more than two dozen AI agents in production and is building an agentic platform with autonomous execution on a stated roadmap.

Norstella operates from 12+ offices across the US, UK, Netherlands, Japan, China, and India, including Global Capability Centers in Bangalore, Gurgaon, and Noida. Leadership includes Executive Chair Fred Hassan, CEO Michael Gallup, CFO Dan Tempesta, and CTO Andrew Augustine. Revenue is not publicly disclosed; based on 1,500–1,600+ headcount and an enterprise SaaS business model, revenue is most plausibly in the $500M–$1B band.

Name

Norstella

Legal name

Caerus US 1, Inc.

Website

https://www.norstella.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Norstella is a global life sciences intelligence company offering AI-powered data, analytics, and consulting solutions to pharmaceutical, biotech, and life sciences organizations across the drug development lifecycle — from pipeline to patient.

Ownership category

akta.pro rank

Product category

Pharmaceutical Intelligence / Life Sciences Analytics

NAICS

Software Publishers (5132), Other Scientific and Technical Consulting Services (54169)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industry

Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)

Keywords

• Pharmaceutical intelligence
• Clinical trial data
• Real-world evidence
• Drug pipeline analytics
• Market access data

Headquarters

HQ city

Yardley

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharma Intelligence SaaS Platforms: Subscription-based access to data and analytics platforms across multiple brands serving pharmaceutical, biotech, and life sciences companies throughout the drug development lifecycle

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Core offering

Norstella is a multi-brand pharmaceutical intelligence platform that provides AI-powered data, analytics, and clinical/commercial intelligence solutions across the entire drug development lifecycle — from pipeline to patient. Through its brands (Citeline, Evaluate, MMIT, Panalgo, Skipta, The Dedham Group), it offers subscription-based SaaS platforms integrating real-world data (74+ billion data points), clinical trial intelligence, market access data, forecasting, and patient journey analytics to pharmaceutical, biotech, and life sciences clients.

Product overview

Norstella is a multi-brand pharma intelligence platform company that provides a unified ecosystem of data, technology, and expertise across the drug development lifecycle — from pipeline to patient. The company is organized around six market-leading brands: Citeline (clinical trial intelligence, pipeline data, and regulatory/commercial publications), Evaluate (market forecasting and commercial intelligence), MMIT (real-world data on drug coverage, patient access, and payer landscapes), Panalgo (instant health data analytics platform), Skipta (HCP digital engagement across 50+ specialty communities), and The Dedham Group (market access strategy consulting). Central to the portfolio is NorstellaLinQ — a fully integrated data asset with 74 billion+ linked data points combining real-world data with proprietary intelligence across all brands. Norstella's own AI engine (Norstella AI) powers decision-making across all brands, with brand-specific AI features including Evaluate Ask Ella (AI analyst for commercial intelligence), MMIT Searchlight (AI-powered policy alerts), Panalgo Ella AI (conversational data querying), Norstella Atlas (AI-powered sourced deliverable generation), and Citeline SmartSolutions (AI-enabled protocol design).

Differentiator

Problem solved

Functional benefit

Brands

• Citeline: Clinical solutions and patient-focused business intelligence offerings for life sciences professionals
• Evaluate
• MMIT
• Panalgo
• Skipta
• The Dedham Group
• NorstellaLinQ
• Norstella AI

Products and services

• NorstellaLinQ The biopharma industry's first fully integrated data asset, combining 74 billion+ linked data points from real-world data (open/closed claims, lab results, EMR) with Norstella's proprietary forecasting, clinical, regulatory, payer, and commercial intelligence across all six Norstella brands.
• Norstella AI

Quantifiable outcome

• 30-60% improvements in enrollment for partnered clinical trial programs
• +2 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

One partnership is on record.

• RecursioncoreStrategic or Co-development Partner · 31 March 2026Expanded strategic partnership where Citeline's real-world data and evidence capabilities integrate with Recursion's AI-enabled ClinTech platform, enabling more precise trial design, improved site selection, and faster development decisions. Partnership has yielded 30-60% improvements in enrollment for partnered programs.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IQVIA: IQVIA is the largest contract research organization and pharma intelligence provider, offering clinical trial services, real-world data, technology solutions, and analytics. It directly overlaps Norstella across clinical trial intelligence, real-world evidence, and commercial analytics for the same pharma/biotech customer base.
• Clarivate: Clarivate provides intellectual property, scientific, and academic research intelligence, including life sciences and pharma R&D analytics. It is a direct competitor to Norstella's pharma intelligence brands, particularly in research analytics, regulatory intelligence, and pipeline data, with overlapping leadership pedigree (Norstella CTO previously served as Clarivate CTO).
• Veeva Systems: Veeva is a leading life sciences cloud platform providing CRM, regulatory, clinical, and quality solutions to pharma and biotech. It directly competes with Norstella's Citeline and Evaluate offerings in clinical trial data, regulatory intelligence, and commercial intelligence, serving overlapping enterprise pharma customers.

Broad incumbents

• ICON plc: ICON is one of the largest global clinical research organizations (CROs) and post-PRA Health Sciences combination provides clinical trial services and analytics to pharma. It is a broad incumbent competing with Norstella's clinical trial intelligence (Citeline) and broader drug development offerings.
• Parexel International: Parexel is a global CRO with biopharmaceutical services spanning clinical research, real-world evidence, and commercialization. It overlaps with Norstella's clinical solutions (Citeline) and broader drug development intelligence offerings as a large established player.

Emerging players

• Definitive Healthcare: Definitive Healthcare provides commercial intelligence on healthcare providers, hospitals, and life sciences companies. It is an emerging player with partial overlap to Norstella's MMIT market access data and Skipta HCP engagement offerings, particularly for U.S. healthcare commercial intelligence.
• Aetion: Aetion is a healthcare analytics company focused on real-world evidence generation for regulatory and payer decision-making. It directly competes with portions of NorstellaLinQ and MMIT's real-world evidence capabilities, particularly for regulatory-grade RWE submissions.
• Tempus AI: Tempus AI is a healthcare AI and precision medicine company leveraging real-world data, genomic sequencing, and AI for clinical and research applications. It is an emerging player that intersects with Norstella's real-world data and AI offerings, particularly in oncology and rare disease markets.
• Flatiron Health: Flatiron Health (a Roche subsidiary) provides oncology-specific real-world data, electronic medical record solutions, and clinical research tools. It overlaps with Norstella's oncology-focused real-world data and clinical intelligence offerings as a specialized competitor.

Others

• Cognizant Life Sciences: Cognizant's life sciences division provides IT services, digital transformation, and consulting to pharma and biotech. It is adjacent to Norstella as a technology and consulting services provider serving overlapping pharma customers, but does not directly compete in pharma intelligence or clinical trial data products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NorstellaCo
• Facebookfacebook.com/NorstellaCo
• LinkedInlinkedin.com/company/norstellacompany

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Norstella